Anti-tuberculosis activity and drug interaction with nevirapine of inhalable lipid microspheres containing rifampicin in murine model

References

• Benedetti S, Dostert P. Induction and autoinduction properties of rifamycin derivatives: A review of animal and human studies. Environ Health Perspect 1994; 102: 101–105
   Web of Science ®Google Scholar
• Burman WJ, Gallicano K, Peloquin C. Therapeutic implication of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin Infect Dis 1999; 28: 419–430
   PubMed Web of Science ®Google Scholar
• Chaisson RE, Clermont HC, Holt EA, Cantave M, Johnson MP, Atkinson J, Davis H, Boulos R, Quinn TC, Halsey NA. The JHU-CDS Research Team. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996; 154: 1034–1038
   PubMedGoogle Scholar
• Chapuis L, Ji B, Truffot-Pernot C, O’Brien RJ, Raviglione MC, Grosset JH. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am J Respir Crit Care Med 1994; 150: 1355–1362
   PubMedGoogle Scholar
• Chen J, Raymond K. Roles of rifampicin in drug-drug interactions: Underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob 2006; 5(3), Available online at: http://www.ann-clinmicrob.com/content/5/1/3, accessed 14 May 2009
   PubMedGoogle Scholar
• Cohen K, van Cutsem G, Boulle A, McIlleron H, Goemaere E, Smith PJ, Maartens G. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother 2008; 61: 389–393
   PubMed Web of Science ®Google Scholar
• Dean GL, Back DJ, Ruiter A. Effect of tuberculosis therapy on nevirapine trough plasma concentrations. AIDS 1999; 13: 2489
   PubMed Web of Science ®Google Scholar
• Dlodlo RA, Fujiwara PI, Enarson DA. Should tuberculosis treatment and control be addressed differently in HIV-infected and uninfected individuals?. Eur Respir J 2005; 25: 751–757
   PubMedGoogle Scholar
• Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metabol Dispos 1999; 27: 1488–1495
   PubMed Web of Science ®Google Scholar
• Garcia-Contreras L, Fiegel J, Telko MJ, Elbert K, Hawi A, Thomas M, VerBerkmoes J, Germishuizen WA, Fourie PB, Hickey AJ, et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother 2007; 51: 2830–2836
   PubMed Web of Science ®Google Scholar
• Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122: 219–226
   PubMed Web of Science ®Google Scholar
• Law KF, Jagirdar J, Weiden MD, Bodkin M, Rom WN. Tuberculosis in HIV-positive patients: Cellular response and immune activation in the lung. Am J Respir Crit Care Med 1996; 153: 1377–1384
   PubMed Web of Science ®Google Scholar
• Manabe YC, Dannenberg Jr AM, Jr. Pathophysiology: Basic aspects. Tuberculosis & nontuberculous mycobacterial infections, D Schlossberg. McGraw-Hill, New York 2006; 18–51
   Google Scholar
• Manosuthi W, Sungkanuparph S, Thakkinstian A, Rattanasiri S, Chaovavanich A, Prasithsirikul W, Likanonsakul S, Ruxrungtham K. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis 2006; 43: 253–255
   PubMed Web of Science ®Google Scholar
• Martigoni M, Groothuis GMM, Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metabol Toxicol 2006; 2: 875–894
   PubMedGoogle Scholar
• Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003; 52: 981–986
   PubMed Web of Science ®Google Scholar
• Penzak SR, Kabuye G, Mugyenyi P, Mbamanya F, Natarajan V, Alfaro RM, Kityo C, Formentini E, Masur H. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med 2007; 8: 86–91
   PubMed Web of Science ®Google Scholar
• Pratt RJ, Grange JM, Williams VG. Tuberculosis and the HIV/AIDS pandemic. Tuberculosis: A foundation for nursing and healthcare practice, RJ Pratt, JM Grange, VG Williams. Hodder Education, London 2005; 131–140
   Google Scholar
• Rabin L, Hincenbergs M, Moreno MB, Warren S, Linquist V, Datema R, Charpiot B, Seifert J, Kaneshima K, Mccune JM. Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus Type 1 compounds. Antimicrob Agents Chemother 1996; 40: 755–762
   PubMed Web of Science ®Google Scholar
• Ramachandram G, Hemanthkumar AK, Rajasekaran S, Padmapriyadarsini C, Narendran G, Sukumar B, Sathishnarayan S, Raja K, Kumaraswami V, Swaminathan S. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. JAIDS 2006; 42: 36–41
   Google Scholar
• Ribera E, Pou L, Lopez RM, Crespo M, Falco V, Ocana I, Ruiz I, Pahissa A. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. JAIDS 2001; 28: 450–453
   Google Scholar
• Sharma R, Muttil P, Yadav AB, Rath SK, Bajpai VK, Mani U, Misra A. Uptake of inhalable microparticles affects defence responses macrophages infected with Mycobacterium tuberculosis H37Ra. J Antimicrob Chemother 2007; 59: 499–506
   PubMed Web of Science ®Google Scholar
• Shen J, He B, Wang B. Effects of lipo-prostaglandin E1 on pulmonary hemodynamics and clinical outcomes in patients with pulmonary arterial hypertension. Chest 2005; 128: 714–719
   PubMedGoogle Scholar
• Takenaga M, Nakagawa T, Igarashi R. Application of lipid microspheres to prepare a thromboxane A2 receptor antagonist aerosol inhalation. J Drug Targ 1993; 1: 293–301
   PubMed Web of Science ®Google Scholar
• Takenaga M, Ohta Y, Tokura Y, Hamaguchi A, Igarashi R, Disratthakit A, Doi N. Lipid microsphere formulation containing rifampicin targets alveolar macrophages. Drug Deliv 2008; 15: 169–175
   PubMed Web of Science ®Google Scholar
• Verma Rahul K, Kaur J, Kumar K, Yadav Awadh B, Misra A. Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob Agents Chemother 2008; 52: 3195–3201
   PubMedGoogle Scholar
• Willson TM, Kliewer SA. PXR, CAR and drug metabolism. Nature Rev 2002; 1: 259–266
   Google Scholar
• World Health Organization. Information Resource Centre HTM/STB. WHO report 2008: Global tuberculosis control: Surveillance, planning, financing. WHO press, Geneva 2008
   Google Scholar